| HOME >> BIOLOGY >> TECHNOLOGY |
CINCINNATI, Aug. 22 /PRNewswire-FirstCall/ -- Kendle (Nasdaq: KNDL), a leading, global full-service clinical research organization (CRO) founded in 1981, today celebrated its 10th anniversary as a public company by ringing the opening bell at the NASDAQ Stock Market. Kendle also marked the anniversary with an Investor Day at the NASDAQ Times Square MarketSite to share with analysts and shareholders the company's perspective on the latest industry trends and growth plans for the future.
(Photo: http://www.newscom.com/cgi-bin/prnh/20070822/CLW086 )
(Logo: http://www.newscom.com/cgi-bin/prnh/20030429/KNDLLOGO )
"We are very proud of Kendle's successes since becoming a public company 10 years ago," noted Candace Kendle, PharmD, Chairman and Chief Executive Officer. "Although we have been in the clinical development industry for more than a quarter of a century, the past 10 years in particular have seen tremendous growth in our capability and capacity to deliver the global clinical development and therapeutic expertise our biopharmaceutical customers want from their CRO partners. As we look back over this important period in our history, our success could not have been achieved without the continued contributions of our more than 3,000 associates worldwide who are committed to making life-saving and life-enhancing drugs a reality for patients around the world. We thank them for their contributions and for the role they will play in our future success.
"Kendle is strongly positioned in the growing outsourced Phase I-IV
drug research and deve
'/>"/>
| SOURCE Kendle International Inc. Copyright©2007 PR Newswire. All rights reserved |